The ketolide class of antimicrobial agents includes telithromycin, the first of that class to be developed for use as a chemotherapeutic agent. 1 In this report we compile data that have been recorded at our institute in order to propose interpretive criteria for the disc diffusion susceptibility test. In addition, we summarize the results of two multilaboratory collaborative studies that were designed to select quality control (QC) limits for telithromycin disc diffusion tests.
Introduction
The ketolide class of antimicrobial agents includes telithromycin, the first of that class to be developed for use as a chemotherapeutic agent. 1 In this report we compile data that have been recorded at our institute in order to propose interpretive criteria for the disc diffusion susceptibility test. In addition, we summarize the results of two multilaboratory collaborative studies that were designed to select quality control (QC) limits for telithromycin disc diffusion tests.
Materials and methods

Antimicrobial susceptibility tests
Disc diffusion and broth microdilution susceptibility tests were performed as outlined by the National Committee for Clinical Laboratory Standards (NCCLS).
2,3 Because structurally related compounds such as the macrolides are tested with a 15 g disc, initial studies of telithromycin used a disc content of 15 g. Subsequently, there were no obvious reasons to consider use of other disc potencies. Disc diffusion tests were performed on Mueller-Hinton agar. When testing streptococci, the agar was supplemented with 5% defibrinated sheep blood and the plates were incubated at 35°C with 5-7% CO 2 . When testing staphylococci, the plates were incubated at 35°C in ambient air. Broth microdilution tests were performed in cation-adjusted MuellerHinton broth; 3% lysed horse blood was added when testing streptococci. Microdilution trays were incubated at 35°C without added CO 2 .
Quality control studies
An initial 10 laboratory study was undertaken in order to propose tentative zone size limits for disc tests of Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619. This study followed the protocol described by the NCCLS 4 except that we used 10 testing facilities rather than the required seven. This initial study involved replicate tests on six different batches of Mueller-Hinton agar from four manufacturers and two batches of 15 g telithromycin discs from different manufacturers. This exercise generated 400 zone diameters and tentative zone size limits were calculated using the statistic of Gavan et al. 5 A 15 g erythromycin disc was also tested as an internal control and that generated 200 zone diameters, Ͼ95% of which were within established QC ranges. To confirm the validity of the tentative control limits, two batches of telithromycin discs from different manufacturers and one batch of erythromycin discs were distributed to 30 clinical laboratories where both control strains were tested on 20 separate days using media obtained from local suppliers. These zones of inhibition were evaluated to determine how often zones fell within the tentative QC ranges that were defined by the initial study.
Microorganisms
In 1997 and again in 1999, fresh clinical isolates were collected from different medical centres throughout North America and susceptibility tests were performed in a central laboratory. Here we combine the results of broth microdilution and disc diffusion tests accumulated during these two surveys. Data were obtained with 2082 staphylococci (1061 S. aureus and 1021 coagulase-negative species), 1123 Streptococcus pneumoniae and 970 other Streptococcus spp. (413 Streptococcus pyogenes, 297 Streptococcus agalactiae, 165 viridans group, 95 other species). Scattergrams were prepared for each of the three major groups of microorganisms. Because MICs were not evenly distributed over a wide range of concentrations, regression statistics were considered inappropriate. Using an error minimization approach, interpretive criteria were proposed for testing staphylococci in ambient air and for testing streptococci with increased CO 2 . Zone size breakpoints were those that minimized interpretive discrepancies between the two types of susceptibility tests.
MIC breakpoints
Like the macrolides, telithromycin tends to concentrate in broncho-pulmonary tissues and in white blood cells. 6 Consequently, the concentration at the site of infection is likely to greatly exceed the concentration in the patient's blood. Telithromycin is administered orally as a single daily dose. Following a 800 mg dose, peak serum concentrations Ͼ2.0 mg/L are anticipated. 7 It is possible that microorganisms with MICs of 1.0 or 2.0 mg/L might respond to therapy but those with MICs of у4.0 mg/L are likely to be resistant. We tentatively adapted conservative MIC breakpoints of р0.5 mg/L as susceptible, 1.0 mg/L as intermediate and у2.0 mg/L as resistant. Scattergrams were then prepared in order to select zone size criteria that would best separate categories defined by those MIC breakpoints.
Results and discussion
QC limits for telithromycin disc tests were defined by an initial 10 laboratory study that generated 400 zone diameter measurements. Those limits were further evaluated by a less rigidly structured 30 laboratory study that should have generated 1200 zone diameters. For logistic reasons, not all 1200 zones were obtained. The overall distribution of zone diameters for S. aureus ATCC 25923 and for S. pneumoniae ATCC 49619 are described in the Table. In both studies, two telithromycin discs from different manufacturers and one erythromycin control disc were placed on each test plate. The Table includes results of all tests with both control strains.
Under the rigidly controlled conditions of the initial study, zone diameters were clustered within a range including 3 mm on either side of the median zone diameter and Ͼ98% of all determinations fell within the proposed 7 mm ranges for each of the control strains. The control erythromycin disc gave 200 zones all within the current QC ranges 2 for each control strain. Under less stringently controlled test conditions in a larger variety of clinical laboratories, using media from local suppliers, the overall range of zone diameters was greater. With the erythromycin control disc, у95% of the reported zones were within accepted limits. 2 However, telithromycin zones were more broadly distributed and only 90-92% fell within the proposed 7 mm ranges. The proportion of tests that fell within the QC limits would be increased if the control ranges were extended by adding 1 mm to either end (9 mm ranges). The initial 7 mm ranges are those that will be included in the NCCLS document. We propose tentative disc test criteria of р19 mm for resistant, 20-22 mm for intermediate and у23 mm for susceptible when testing Staphylococcus spp. Among 2082 staphylococci, 629 strains were resistant (MICs of у2.0 mg/L) and five (0.8%) of those resistant strains were susceptible by the disc test (very major discrepancies, which were not confirmed by retesting). Furthermore, three (0.2%) of 1447 susceptible strains were resistant by the disc test (major discrepancies, which were not retested). There was no obvious explanation for the few discrepancies between broth microdilution and disc diffusion tests.
Because the streptococci were incubated in 5-7% CO 2 , slightly smaller zone diameters might be anticipated. For testing S. pneumoniae and other streptococci, interpretive zone size criteria can be reduced to р16 mm for resistant, 17-19 mm for intermediate and у20 mm for susceptible. Telithromycin-resistant streptococci were extremely uncommon in our collection of isolates and thus we cannot properly assess the accuracy of the zone size criteria for the resistant category. The overall discrepancy rates for disc tests of pneumococci and other streptococci combined were: р0.1% very major, р0.2% major and р1.3% minor differences. Fourteen of the 15 strains with intermediate MICs of 1.0 mg/L gave large zones of inhibition and appear to be part of the normally distributed susceptible population. Those strains were not subjected to replicate testing in order to determine how often their MICs might move from intermediate to susceptible or resistant categories.
Additional tests with enterococci were not as successful (data not shown). The disc test should not be used for evaluating telithromycin against enterococci because of an unacceptable number of discrepant results. Because enterococcal infections are not likely to be treated with telithromycin, we did not try to set interpretive criteria for that genus. For the other Gram-positive cocci, the disc test appears to be reasonably accurate.
The results presented here are part of the information package that is currently being considered by the US Food and Drug Administration and will soon be presented to the NCCLS subcommittee for antimicrobial susceptibility tests. QC ranges proposed here have been accepted by the NCCLS subcommittee for antimicrobial susceptibility tests. Official judgments concerning interpretive criteria for tests of telithromycin have not yet been established for the NCCLS methods. In the interim, our provisional criteria might be useful to those who wish to test telithromycin by NCCLS methods. Susceptibility tests performed by other procedures may require slightly different interpretive criteria or QC limits. 
